Clinical Study Data Request Registered Users, Please Login

Find by:

Study ID:
Medicine:
Phase:

A Three-Month, Randomized, Double-Masked, Parallel-Group Study with a Planned Three-Month Safety Extension of the Efficacy and Safety of a Fixed Combination of Brinzolamide 1 %/Brimonidine 0.2 % Compared to Brinzolamide 1 % and Brimonidine 0.2 % All Dosed Three Times Daily in Patients with Open-Angle Glaucoma and/or Ocular Hypertension
brinzolamide
C-10-039
NCT01297920
Open-Angle Glaucoma; Ocular Hypertension
Phase 3
 
Alcon is a division of Novartis
June 2016

Powered by ideaPoint, Inc.